Kezar Life Sciences Inc (KZR)

07:26 AM

When (KZR) Moves Investors should Listen - news.stocktradersdaily.com

07:26 AM

04:01 AM

Kezar Life Sciences to Participate in the Jefferies Global Healthcare Conference - Business Wire

04:01 AM

May 27, 2025

Kezar Life Sciences (KZR) Upgraded to Buy: What Does It Mean for the Stock? - Nasdaq

May 27, 2025

May 23, 2025

Kezar Life Sciences Reports Positive Trial Results - TipRanks

May 23, 2025

May 18, 2025

Where are the Opportunities in (KZR) - news.stocktradersdaily.com

May 18, 2025

May 18, 2025

Dimensional Fund Advisors LP Takes $217,000 Position in Kezar Life Sciences, Inc. (NASDAQ:KZR) - Defense World

May 18, 2025

May 17, 2025

Q2 EPS Estimate for Kezar Life Sciences Raised by Analyst - Defense World

May 17, 2025

May 15, 2025

Wells Fargo & Company MN Sells 71,985 Shares of Kezar Life Sciences, Inc. (NASDAQ:KZR) - Defense World

May 15, 2025

May 14, 2025

KZR Reports Financial Status and Progress in AIH Treatment Trials | KZR Stock News - GuruFocus

May 14, 2025

May 13, 2025

Kezar Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update - The Joplin Globe

May 13, 2025

May 07, 2025

(KZR) Trading Signals - news.stocktradersdaily.com

May 07, 2025

May 07, 2025

Kezar Life Sciences, Inc. (NASDAQ:KZR) Shares Purchased by JPMorgan Chase & Co. - Defense World

May 07, 2025

May 05, 2025

Kezar Life Sciences Inc expected to post a loss of $2.60 a shareEarnings Preview - TradingView

May 05, 2025

May 03, 2025

Geode Capital Management LLC Lowers Position in Kezar Life Sciences, Inc. (NASDAQ:KZR) - Defense World

May 03, 2025

May 01, 2025

Kezar Life Sciences (KZR) Expected to Announce Quarterly Earnings on Thursday - Defense World

May 01, 2025

Apr 22, 2025

(KZR) Technical Data - news.stocktradersdaily.com

Apr 22, 2025

Apr 13, 2025

Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Business Wire

Apr 13, 2025

Apr 06, 2025

Trend Tracker for (KZR) - news.stocktradersdaily.com

Apr 06, 2025

Apr 03, 2025

Kezar Life Sciences stock hits 52-week low at $4.36 By Investing.com - Investing.com South Africa

Apr 03, 2025

Apr 03, 2025

Kezar Life Sciences stock hits 52-week low at $4.36 - Investing.com

Apr 03, 2025

Apr 02, 2025

Polymyositis Market Predicted to See Upsurge Through 2034, - openPR.com

Apr 02, 2025

Apr 01, 2025

Kezar Life Sciences Appoints New Principal Accounting Officer - TipRanks

Apr 01, 2025

Mar 29, 2025

What is William Blair’s Forecast for KZR Q1 Earnings? - Defense World

Mar 29, 2025

Mar 26, 2025

KZR stock touches 52-week low at $5.20 amid market challenges By Investing.com - Investing.com South Africa

Mar 26, 2025

Mar 26, 2025

KZR stock touches 52-week low at $5.20 amid market challenges - Investing.com Australia

Mar 26, 2025

Mar 26, 2025

Kezar Life Sciences Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis (AIH) and Reports Fourth Quarter and Year End 2024 Financial Results - BioSpace

Mar 26, 2025

Mar 25, 2025

Kezar reports positive AIH trial results, financials for 2024 By Investing.com - Investing.com South Africa

Mar 25, 2025

Mar 25, 2025

Promising Clinical Trial Results and Safety Profile Justify Buy Rating for Kezar Life Sciences - TipRanks

Mar 25, 2025

Mar 25, 2025

Kezar stock drops on Q4 results, trial data (KZR:NASDAQ) - Seeking Alpha

Mar 25, 2025

Mar 25, 2025

Kezar Life Sciences Touts Positive Data From Mid-Stage Study For Chronic Liver Disease Drug Candidate - Benzinga

Mar 25, 2025

Mar 25, 2025

Kezar reports positive AIH trial results, financials for 2024 - Investing.com India

Mar 25, 2025

Mar 25, 2025

Kezar Life Sciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 25, 2025

Mar 25, 2025

KEZAR LIFE SCIENCES Earnings Results: $KZR Reports Quarterly Earnings - Nasdaq

Mar 25, 2025

Mar 25, 2025

Breakthrough in Autoimmune Hepatitis: Kezar's Drug Achieves 36% Response Rate While Placebo Shows Zero - Stock Titan

Mar 25, 2025

Mar 24, 2025

Kezar Life Sciences to Present Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis on March 25, 2025 - BioSpace

Mar 24, 2025

Mar 24, 2025

Major Clinical Trial Results: New Autoimmune Hepatitis Treatment Shows PromiseData Reveal Coming - Stock Titan

Mar 24, 2025

Mar 23, 2025

Amundi Sells 74,019 Shares of Kezar Life Sciences, Inc. (NASDAQ:KZR) - Defense World

Mar 23, 2025

Mar 17, 2025

KEZAR LIFE SCIENCES INC- The GF Score's 5 Key Aspects of Analysis - GuruFocus.com

Mar 17, 2025

Mar 16, 2025

How the (KZR) price action is used to our Advantage - news.stocktradersdaily.com

Mar 16, 2025

Mar 12, 2025

Dermatomyositis Drug Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Treatment Market, Prevalence, Medication, Statistics, Therapies, Companies by DelveInsight - The Globe and Mail

Mar 12, 2025

Mar 10, 2025

Kezar Life Sciences Inc expected to post a loss of $2.88 a shareEarnings Preview - TradingView

Mar 10, 2025

Mar 03, 2025

Kezar Life Sciences’ (KZR) Outperform Rating Reiterated at William Blair - Defense World

Mar 03, 2025

Feb 28, 2025

Kezar stock rating raised to Outperform at William Blair By Investing.com - Investing.com UK

Feb 28, 2025

Feb 24, 2025

Dermatomyositis Market Generated Opportunities, Future Scope - openPR

Feb 24, 2025

Feb 23, 2025

(KZR) On The My Stocks Page - Stock Traders Daily

Feb 23, 2025

Feb 21, 2025

Kezar Life Sciences (KZR) Stock Price, News & Analysis - MarketBeat

Feb 21, 2025

Feb 21, 2025

Activist investor threatens Peninsula drug maker's merger plans - The Business Journals

Feb 21, 2025

Feb 18, 2025

Kezar Life Sciences to Present at Virtual KOL Event Hosted by William Blair on Zetomipzomib Clinical Development in Autoimmune Hepatitis and Provide a Safety Update from the PALIZADE Trial for Lupus Nephritis on February 27, 2025 - Business Wire

Feb 18, 2025

Feb 12, 2025

Objective long/short (KZR) Report - Stock Traders Daily

Feb 12, 2025